ICAM1 and cholangiocarcinoma: In comparison with existing CCA therapeutics, our ICAM1 ADCs feature following advantages: first, we identified ICAM1 as an effective cell membrane protein target for CCA, which can be broadly used for developing many targeting therapeutic modalities including ADCs, CAR-T/NK/macrophage cell therapies, and oncolytic viruses.